KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aquestive Therapeutics (AQST) Other Operating Expenses (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Other Operating Expenses data on record, last reported at $5.8 million in Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 29.12% year-over-year to $5.8 million; the TTM value through Dec 2025 reached $18.6 million, up 3.82%, while the annual FY2025 figure was $18.6 million, 3.82% up from the prior year.
  • Other Operating Expenses reached $5.8 million in Q4 2025 per AQST's latest filing, up from $4.5 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $6.6 million in Q2 2023 and bottomed at $2.8 million in Q1 2021.
  • Average Other Operating Expenses over 5 years is $4.6 million, with a median of $4.5 million recorded in 2024.
  • Peak YoY movement for Other Operating Expenses: surged 57.61% in 2022, then plummeted 31.6% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $3.4 million in 2021, then soared by 57.61% to $5.3 million in 2022, then decreased by 11.8% to $4.7 million in 2023, then decreased by 3.4% to $4.5 million in 2024, then increased by 29.12% to $5.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $5.8 million in Q4 2025, $4.5 million in Q3 2025, and $4.6 million in Q2 2025.